Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Weekly paclitaxel--an effective treatment for advanced breast cancer.

Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R, Järvenpää R, Lehtinen I, Maiche A, Kaleva-Kerola J, Huusko M, Möykkynen K, Ala-Luhtala T.

Anticancer Res. 2013 Jun;33(6):2623-7.

PMID:
23749918
2.

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Dec;7(11):850-6. doi: 10.3816/CBC.2007.n.049.

PMID:
18269774
3.

Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.

Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF.

Clin Breast Cancer. 2002 Dec;3(5):346-52.

PMID:
12533265
4.
5.

Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K.

Acta Oncol. 2004;43(1):11-4.

PMID:
15068314
6.

Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).

Sato K, Inoue K, Saito T, Kai T, Mihara H, Okubo K, Koh J, Mochizuki H, Tabei T; Saitama Breast Cancer Clinical Study Group..

Jpn J Clin Oncol. 2003 Aug;33(8):371-6.

PMID:
14523055
7.
8.

[Weekly paclitaxel therapy for metastatic breast cancer].

Kokufu I, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K.

Gan To Kagaku Ryoho. 2002 Feb;29(2):221-6. Japanese.

PMID:
11865627
9.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Caratení G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.

PMID:
9694607
10.

Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.

Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-87-S17-90.

PMID:
9374102
11.

[Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].

Emoto T, Yoshikawa K, Yoshioka Y, Nezu R, Fujikawa M, Fujii M, Maeda S, Naka Y, Komaki T.

Gan To Kagaku Ryoho. 2003 Jun;30(6):817-22. Japanese.

PMID:
12852349
12.
13.

Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients.

Baltali E, Altundag K, Ozisik Y, Guler N, Tekuzman G.

Tohoku J Exp Med. 2004 Jul;203(3):205-10.

14.

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.

Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G.

Cancer Chemother Pharmacol. 2009 Apr;63(5):953-8. doi: 10.1007/s00280-008-0821-8.

PMID:
18716777
15.

Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer.

Watatani M, Ueda K, Daito K, Azumi T, Hirai T, Yamato M, Hojo T, Hirai K, Inui H, Shiozaki H.

Breast Cancer. 2004;11(2):187-93.

PMID:
15550866
16.

Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.

Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T.

Anticancer Res. 2009 Feb;29(2):625-30.

17.

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P.

Br J Cancer. 1996 Aug;74(4):650-6.

18.

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, et al.

J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75.

PMID:
7674322
20.

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.

Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.

Cancer. 1998 Jan 1;82(1):134-40.

PMID:
9428489

Supplemental Content

Support Center